Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04162899 |
| Consolidated Lead Sponsor | Reistone Biopharma Company Limited |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 105 participants (ACTUAL) |
| Registered Start Date | 2019-11-06 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Xuanwu Hospital Capital Medical University | Beijing, China | Open Hospital Dossier -> |
| Peking University Third Hospital | Beijing, China | Open Hospital Dossier -> |
| Peking Union Medical College Hospital | Beijing, China | Open Hospital Dossier -> |
| The Second Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.